Exciting news over the past few days... Your valuation concerns suggest you don't understand what you're invested in. This IP portfolio will be licensing technology globally while other companies are still trying to figure out basic separation. Your post shows a fundamental misunderstanding of what makes IXR's IP portfolio in process, Separation of EOL Magnets and MREC into Separated High Purity REOs
IXR didn't just buy some random technology - they acquired 100% of SerenTech in April 2022, which came with an exclusive "patent and know-how" licence from Queen's University, Belfast for the groundbreaking Multifunctional Amide Ionic Liquids (MAIL) technology.
IXR’s intellectual property isn’t just a patent on paper—it’s a combination of patented processes, proprietary know-how, and a highly specialized team developed over years (2015) at Queen’s University Belfast and now commercialized in Belfast. This technology, especially the Multifunctional Amide Ionic Liquids (MAIL) platform, isn’t something that can simply be “reverse engineered” by seeing the end product. The real value is in the deep chemical expertise, process control, and integration—none of which are visible from a finished REO sample.
While no system is 100% immune to IP risk, IXR’s moat is built on more than paperwork. It’s the combination of proprietary chemistry, operational know-how, and first-mover status in a sector that governments are now watching very closely. If anything, the fact that others want to copy it is proof of just how valuable IXR’s IP really is.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)